Breast Neoplasm research hub

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

This study looks at new treatments for triple negative breast cancer that hasn't fully responded to initial chemotherapy. We're testing if medicines, given briefly before surgery, can start to shrink the cancer or change it in helpful ways.